TY - JOUR T1 - Can we predict early 7-day readmissions using a standard 30-day hospital readmission risk prediction model? JF - medRxiv DO - 10.1101/19012468 SP - 19012468 AU - Sameh N. Saleh AU - Anil N. Makam AU - Ethan A. Halm AU - Oanh Kieu Nguyen Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/27/19012468.abstract N2 - Despite focus on preventing 30-day readmissions, early readmissions (within 7 days of discharge) may be more preventable than later readmissions (8-30 days). We assessed how well a previously validated 30-day readmission prediction model predicts 7-day readmissions. We re-derived model coefficients for the same predictors as in the original 30-day model to optimize prediction of 7-day readmissions. We compared model performance and compared differences in strength of model factors between the 7-day model to the 30-day model. While there was no substantial change in model performance between the original 30-day and the re-derived 7-day model, there was significant change in strength of predictors. Characteristics at discharge were more predictive of 7-day readmissions, while baseline characteristics were less predictive. Improvements in predicting early 7-day readmissions will likely require new risk factors proximal to the day of discharge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Agency for Healthcare Research and Quality-funded UT Southwestern Center for Patient-Centered Outcomes Research (R24HS022418). Dr. Makam is funded by the National Institute on Aging (K23AG052603). Dr. Nguyen is funded by the National Heart, Lung, and Blood Institute (K23HL133441). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from UT Southwestern but restrictions apply to the availability of these data, which were used under approval for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of UT Southwestern. ER -